Science Immunology | Intratumoral Treg Cell Ablation Elicits NK Cell-Mediated Anti-Tumor Immunity

This study reveals the critical role of Treg cells in suppressing NK cell anti-tumor activity, offering new insights for designing combination therapies targeting immunosuppression in the tumor microenvironment, particularly with significant implications for treating CD8 T cell-resistant tumors.

 

Literature Overview

The study titled 'Intratumoral Treg Cell Ablation Elicits NK Cell-Mediated Control of CD8 T Cell-Resistant Tumors,' published in Science Immunology, systematically investigates how Treg cells promote immune escape by suppressing NK cell activity in MHC I-deficient tumors. It demonstrates that local ablation of Treg cells activates the cDC2-CD4 Tconv-IL-2 axis, thereby driving NK cell-mediated tumor control. Using multiple tumor models and genetic tools, the study elucidates the central role of Treg cells in regulating NK cell function, providing a novel mechanism to overcome CD8 T cell resistance.

Background Knowledge

Currently, loss of MHC I expression is a major mechanism of tumor immune escape, preventing CD8 T cells from recognizing tumor cells and thereby limiting the efficacy of T cell-targeted therapies such as checkpoint inhibitors. Although NK cells can recognize tumor cells with low MHC I expression via 'missing-self' recognition, their anti-tumor activity in solid tumors is often constrained by suppressive factors within the tumor microenvironment. Treg cells, a well-known immunosuppressive T cell subset, inhibit effector T cells and NK cells through mechanisms such as secretion of TGF-β and IL-10, and competition for IL-2. However, systemic depletion of Treg cells leads to severe autoimmune toxicity, limiting clinical application. Therefore, selectively targeting intratumoral Treg cells while avoiding systemic toxicity remains a major challenge. This study focuses on whether localized Treg cell depletion can specifically activate NK cells to control CD8 T cell-resistant tumors, and investigates the underlying cellular and molecular mechanisms, particularly the roles of cDC2, CD4 Tconv, and IL-2.

 

 

Research Methods and Experiments

The authors utilized the Foxp3^DTR-GFP transgenic mouse model to achieve specific ablation of intratumoral Treg cells via local injection of diphtheria toxin (DT). Multiple MHC I-deficient tumor models—including MC38-B2m^−/−, B16F10-B2m^−/−, and RMA-B2m^−/−—were used to evaluate tumor growth control. Tumor-infiltrating immune cells were analyzed by flow cytometry, and RNA-seq was employed to systematically characterize transcriptional changes in NK cells. Using DC-deficient models such as Zbtb46^DTR, Batf3^−/−, and Zeb3Δ, the necessity of cDC2 in anti-tumor immunity was established. Additionally, systemic treatments with anti-CCR8 and anti-CTLA4 antibodies were tested in wild-type mice to validate therapeutic efficacy, enhancing the study’s translational relevance.

Key Conclusions and Perspectives

• Local depletion of Treg cells effectively controls MHC I-deficient tumors without triggering systemic autoimmune responses, indicating superior safety compared to systemic Treg depletion strategies.
• NK cells and CD4 Tconv cells are essential for tumor control, whereas CD8 T cells are dispensable, highlighting the critical role of NK cells in CD8-resistant tumors.
• Following Treg cell ablation, NK cell activation, maturation, and cytotoxic function are significantly enhanced, evidenced by upregulation of granzyme B, perforin, and activation markers CD69, SCA-1, and KLRG1, a process dependent on CD4 Tconv cells.
• cDC2 cells, not cDC1, are pivotal in mediating NK cell-dependent tumor control by promoting IL-2 production from CD4 Tconv cells.
• The IL-2 signaling pathway is central to NK cell activation; neutralizing IL-2 completely abrogates tumor control, while exogenous IL-2-MSA restores anti-tumor effects in the absence of CD4 Tconv cells.
• Clinically relevant antibodies such as anti-CCR8 selectively deplete intratumoral Treg cells, activate NK cells, and control tumor growth, supporting their potential as a therapeutic strategy.

Research Significance and Prospects

This study provides a new perspective for cancer immunotherapy, demonstrating that targeting Treg cells not only enhances T cell responses but also activates NK cells via an IL-2-dependent mechanism, broadening the applicability of Treg-targeted therapies. For tumors with MHC I loss or CD8 T cell exhaustion, activating NK cells may serve as an effective alternative. The cDC2-CD4 Tconv-IL-2-NK axis revealed in this study offers a novel target for combination therapies, such as pairing Treg-depleting antibodies with IL-2 superagonists, or vaccines designed to enhance cDC2 function.

 

 

Conclusion

This study systematically elucidates the mechanism by which intratumoral Treg cells suppress NK cell anti-tumor function through inhibition of the cDC2-CD4 Tconv-IL-2 axis. Local ablation of Treg cells relieves NK cell suppression and activates their cytotoxic potential, enabling control of both MHC I-deficient and some MHC I+ tumors. These findings not only reveal a novel function of Treg cells in regulating NK cells but also provide a viable strategy for treating CD8 T cell-resistant tumors. From bench to bedside, this mechanism supports the development of therapies targeting Treg cells in the tumor microenvironment, such as anti-CCR8 antibodies combined with IL-2 pathway agonists to enhance NK cell activity. Furthermore, cDC2-targeted vaccines or cell therapies could amplify this immune axis, offering new hope for patients with refractory tumors. This work lays the foundation for constructing a more comprehensive tumor immune regulatory network, advancing the therapeutic paradigm from 'T cell-centric' to 'pleiotropic immune activation'.

 

Chenyu Zhang, Charles Chien, Eglė Jurgaitytė, Michel DuPage, and David Raulet. Intratumoral Treg Cell Ablation Elicits NK Cell-Mediated Control of CD8 T Cell-Resistant Tumors. Science immunology.